Threshold Pharmaceuticals Announces Its Phase 3 Trial of TH-302 in Patients With Advanced Soft Tissue Sarcoma Will Continue as Planned Following Protocol-Specified Interim Analysis

Marketwired
Threshold Pharmaceuticals Announces Its Phase 3 Trial of TH-302 in Patients With Advanced Soft Tissue Sarcoma Will Continue as Planned Following Protocol-Specified Interim Analysis
Threshold Pharmaceuticals, Inc. Logo
View Comments (0)